Current Report Filing (8-k)
June 02 2020 - 5:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 2, 2020
Menlo Therapeutics Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-38356
|
|
45-3757789
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
520 U.S. Highway 22, Suite 204
Bridgewater, New Jersey 08807
(Address of principal executive offices,
including Zip Code)
(800) 755-7936
(Registrant’s telephone number,
including area code)
(Former name or former address, if changed
since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name of each
exchange on which registered
|
Common
Stock, $0.0001 par value
|
|
MNLO
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item
8.01 Other Events.
On
June 2, 2020, members of senior management of Menlo Therapeutics Inc. (the “Company”) used the Investor Presentation
attached as Exhibit 99.1 (the “Presentation”) to this report in connection with providing a corporate overview at
the Jefferies Virtual Healthcare Conference. The copy of the Presentation filed herewith includes a revision to slide 21 of the
Investor Presentation that was previously filed by the Company on June 2, 2020.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
The
following exhibit is filed herewith.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
MENLO
THERAPEUTICS INC.
|
|
|
|
|
|
Date:
June 2, 2020
|
By:
|
/s/
Mutya Harsch
|
|
|
Mutya Harsch
|
|
|
Chief Legal Officer and General Counsel
|
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Apr 2023 to Apr 2024